Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02009488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canagliflozin, 100 mg
DRUG: Canagliflozin, 300 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC